ClinicalTrials.gg
Status unknownNCT01775917Updated Jun 3, 2014

The Role of Uterine Artery Doppler Parameters in the Management of Retained Products of Conception.

An observational study in Missed Abortion, Incomplete Abortion and Uterine Gestational Residua, sponsored by Carmel Medical Center. Status unknown at 1 site in Israel. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2014-06-03.

Sponsored by Carmel Medical Center · Observational

The sponsor has not verified this record recently (last verified Jun 2014), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Time perspective
Prospective
Enrollment
200
Ages
20 Years to 45 Years
Sex
Female
01

Study summary

During the recent decades the need for surgical evacuation of the uterus in early miscarriages and incomplete miscarriages has been questioned.

It has been shown that an observational approach can be, in many cases, as good as an invasive one without increasing the incidence of uterine infections.

it has been shown that misoprostol - prostaglandin E1 given for missed abortions is successful in emptying the uterus in 85% of cases without any need for surgical intervention. and during recent years many women prefer this approach than the surgical one .

Many have tried using sonographic signs such as endometrial thickness, the presence of a gestational sac, and color doppler to differ between blood clots and a gestational residua in uterus, and to decide according to these signs wether there is a need for surgical evacuation or an expectant management could be used. but none of these methods have been proven to be completely efficient as predictors.

In this study the investigators will examine whether the doppler indices in the uterine arteries can help to predict which gestational residua needs surgical evacuation of the uterus and which could be managed expectantly.

The study hypothesis is that the resistance in uterine artery doppler will be lower in cases with intrauterine residua as opposed to high resistance in cases without residua.

Read the detailed description

It's a prospective observational study that will take place in the gynecology department in Carmel medical center in Haifa, Israel.

The study population are women with the diagnosis of missed abortion matching 8 weeks of pregnancy or less, incomplete abortion or anembryonic pregnancy that are treated with misoprostol in the gynecologic emergency room according to the department's protocol.

our department's protocol for the treatment of missed abortion matching 8 weeks of pregnancy or less, anembryonic pregnancy or incomplete abortions . these women usually get a full explanation from the doctor in the emergency room about the possible treatments :

  1. surgical evacuation i.e. dilatation and curettage
  2. treatment with misoprostol 800 mcg given vaginally. both treatments are used routinely in our emergency room. If the woman chooses the treatment with misoprostol she will then also be told about the study and if she agrees to participate in the study she will sign an informed consent form.

After getting the first dose of misoprostol 800 mcg vaginally the woman is usually discharged home and then a sonographic follow up will be done on several preset occasions where an ultrasound is done vaginally and few sonographic indices are examined : the presence of gestational sac or gestational residua and its size, color doppler for the residua, the size of uterus... in addition to these indices routinely examined during the follow up according to the department protocol we will examine in this study the indices of uterine artery doppler (i.e. S/D ratio, resistance index, pulsatility index).

according to the department protocol day 3 will be the first day of follow up , if a gestational sac is still seen in the uterus, or an endometrial thickness above 30 mm, a second dose of misoprostol is given, and the women will be reexamined on day 10, then a surgical evacuation is performed if we still have the same findings (gestational sac or endometrium >30mm) otherwise the woman is discharged and the last follow up will be on day 4-5 of her next menstruation, that's when it will be decided if the abortion is complete and the uterus is completely empty. if a gestational residua is found after the menstruation then the woman will have to go through surgical evacuation .

In the end we will compare the uterine artery doppler indices of the women with complete abortions to those with failed misoprostol treatment who needed surgical evacuation .

No change in the treatment will be done during the study based on the uterine artery doppler indices , it's only an observational study .

02

Conditions studied

  • Missed Abortion
  • Incomplete Abortion
  • Uterine Gestational Residua
  • Uterine Artery Doppler
03

In context

Abortion, Missed

48 studies on the registry are indexed under Abortion, Missed; 10 are open to participants now.

Browse Abortion, Missed studies →

Lead sponsor

Carmel Medical Center is the lead sponsor of 119 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

women of age 20-45 with missed abortion up to 8 weeks of pregnancy or incomplete abortion treated with misoprostol in the emergency room

Eligibility criteria

Inclusion Criteria:1. women with missed abortion (embryo karger than 5 mm with no heart beat) or anembryonic pregnancy (empty gestational sac larger than 20 mm) 2. incomplete abortion 3. missed abortion with CRL (crown ump length) no larger than 8 weeks of pregnancy 4. women who got a clear explanation about all treatment options and they chose misoprostol as a treatment 5. women who read and signed an form

Exclusion Criteria:

  1. known allergy to prostaglandins or NSAIDS
  2. heavy vaginal bleeding and hemodynamic instability
  3. multifetal gestation
  4. women with a clotting problems or treated with anticoagulant medications
  5. fever above 37.5 c
  6. anemia with \< 9/5 gr%
  7. missed abortion with CRL larger than 8 weeks of pregnancy
  8. diseases that can be aggravated by prostaglandins : severe asthma, uncontrolled blood pressure, glaucoma, sickle cell anemia, mitral stenosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
6 Weeks
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. uterine artery doppler parameters

    comparison between uterine artery doppler parameters after complete abortion with misoprostol to doppler parameters in incomplete abortion with the need of surgical uterine evacuation. and in result to try and find a doppler value that could be used to predict the success of observational management in incomplete abortions or abortions with misoprostol.

    Time frame: 1 year

Secondary outcomes

  1. success rate of treatment of misoprostol in missed and incomplete abortions

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Carmel Medical Center
    Haifa, Israel
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01775917
Responsible party
Sponsor
First posted
Jan 25, 2013
Start date
Jan 2013
Primary completion
Jan 2015 (estimated)
Completion
Jan 2015 (estimated)
Last update
Jun 3, 2014

Study contacts

grace younes, MD
Contact
graceyounes@gmail.com
972508845924
Grace Younes, M.D
principal investigator · Carmel Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion